Immix Biopharma, Inc. (NASDAQ:IMMX) Given Consensus Rating of “Moderate Buy” by Brokerages

Immix Biopharma, Inc. (NASDAQ:IMMX) has earned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $19.50.

Several equities analysts have recently commented on IMMX shares. HC Wainwright upped their price target on Immix Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Friday. Wall Street Zen downgraded Immix Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Morgan Stanley began coverage on Immix Biopharma in a report on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 price objective on the stock. Citizens Jmp reiterated a “market outperform” rating and issued a $23.00 price objective on shares of Immix Biopharma in a report on Friday, March 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research note on Tuesday, April 21st.

Immix Biopharma Stock Performance

Shares of IMMX opened at $8.78 on Friday. The stock has a 50 day moving average price of $9.46 and a 200 day moving average price of $7.09. The stock has a market capitalization of $477.72 million, a price-to-earnings ratio of -9.54 and a beta of 0.12. Immix Biopharma has a one year low of $1.87 and a one year high of $11.61.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. On average, analysts predict that Immix Biopharma will post -0.78 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC purchased a new position in shares of Immix Biopharma in the 4th quarter valued at approximately $20,471,000. Eventide Asset Management LLC acquired a new stake in shares of Immix Biopharma in the 4th quarter valued at approximately $13,331,000. Marshall Wace LLP lifted its holdings in shares of Immix Biopharma by 3,495.4% in the 4th quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock valued at $10,349,000 after buying an additional 1,923,708 shares during the period. Millennium Management LLC acquired a new stake in shares of Immix Biopharma in the 4th quarter valued at approximately $8,681,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Immix Biopharma in the 4th quarter valued at approximately $7,845,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.